Julie A Johnson

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi Pharmacogenetics in clinical practice: how far have we come and where are we going?
    Julie A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, PO Box 100486, Gainesville, FL 32610 0486, USA
    Pharmacogenomics 14:835-43. 2013
  2. ncbi Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array
    J A Johnson
    Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 92:437-9. 2012
  3. ncbi Advancing management of hypertension through pharmacogenomics
    Julie A Johnson
    Colleges of Pharmacy and Medicine and Center for Pharmacogenomics, University of Florida, Gainesville, Florida 100486, USA
    Ann Med 44:S17-22. 2012
  4. ncbi Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 10:47. 2012
  5. ncbi Clopidogrel: a case for indication-specific pharmacogenetics
    J A Johnson
    College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA
    Clin Pharmacol Ther 91:774-6. 2012
  6. ncbi Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial
    Benjamin French
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, Pennsylvania 19104, USA
    Trials 11:108. 2010
  7. ncbi Drug target pharmacogenomics: an overview
    J A Johnson
    Department of Pharmacy Practice, University of Florida, Gainesville, Florida 32610 0486, USA
    Am J Pharmacogenomics 1:271-81. 2001
  8. ncbi Cardiovascular pharmacogenomics
    Julie A Johnson
    UF Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA
    Exp Physiol 90:283-9. 2005
  9. ncbi Pharmacogenomics: application to the management of cardiovascular disease
    J A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:519-31. 2011
  10. ncbi Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
    J A Johnson
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:625-9. 2011

Research Grants

  1. Pharmacogenomic Evaluation of Antihypertensive Responses
    Julie Johnson; Fiscal Year: 2007
  2. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
  3. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
  4. BETA-ADRENERGIC RECEPTOR POLYMORPHISMS AND HYPERTENSION
    Julie Johnson; Fiscal Year: 2003
  5. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002

Detail Information

Publications96

  1. ncbi Pharmacogenetics in clinical practice: how far have we come and where are we going?
    Julie A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, PO Box 100486, Gainesville, FL 32610 0486, USA
    Pharmacogenomics 14:835-43. 2013
    ..The advances and challenges in these areas are described and predictions about future use of genetics in drug therapy are discussed...
  2. ncbi Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array
    J A Johnson
    Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 92:437-9. 2012
    ....
  3. ncbi Advancing management of hypertension through pharmacogenomics
    Julie A Johnson
    Colleges of Pharmacy and Medicine and Center for Pharmacogenomics, University of Florida, Gainesville, Florida 100486, USA
    Ann Med 44:S17-22. 2012
    ..The next decade should clearly define the potential clinical implications of the research in hypertension pharmacogenomics that is currently in progress...
  4. ncbi Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 10:47. 2012
    ....
  5. ncbi Clopidogrel: a case for indication-specific pharmacogenetics
    J A Johnson
    College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA
    Clin Pharmacol Ther 91:774-6. 2012
    ....
  6. ncbi Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial
    Benjamin French
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, Pennsylvania 19104, USA
    Trials 11:108. 2010
    ....
  7. ncbi Drug target pharmacogenomics: an overview
    J A Johnson
    Department of Pharmacy Practice, University of Florida, Gainesville, Florida 32610 0486, USA
    Am J Pharmacogenomics 1:271-81. 2001
    ..Pharmacogenomics has the potential to significantly enhance the ability of clinicians to use medications in a safe and effective manner and, as such, represents an exciting field with tremendous clinical potential...
  8. ncbi Cardiovascular pharmacogenomics
    Julie A Johnson
    UF Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA
    Exp Physiol 90:283-9. 2005
    ....
  9. ncbi Pharmacogenomics: application to the management of cardiovascular disease
    J A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:519-31. 2011
    ..In summary, pharmacogenomics has current applications in the management of cardiovascular disease, with clinically relevant data continuing to mount...
  10. ncbi Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
    J A Johnson
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:625-9. 2011
    ..pharmgkb.org based on new developments in the field.(1)...
  11. ncbi Hypertension pharmacogenomics: current status and future directions
    Julie A Johnson
    University of Florida, Departments of Pharmacy Practice and Medicine Cardiology and Center for Pharmacogenomics, Box 100486, Gainesville, FL 32610 0486, USA
    Curr Opin Mol Ther 7:218-25. 2005
    ..Hypertension pharmacogenomics holds tremendous potential for providing a mechanism by which management of hypertensive patients might be improved, and future studies should help move this field towards its clinical potential...
  12. ncbi Pharmacogenomics of antihypertensive drugs: past, present and future
    Julie A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Box 100486, Gainesville, FL 32610 0486, USA
    Pharmacogenomics 11:487-91. 2010
    ..The next decade should clearly define the clinical potential for hypertension pharmacogenomics...
  13. ncbi Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions
    J A Johnson
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 89:366-78. 2011
    ..We emphasize the linking of clinical results to molecular mechanisms, discuss study design limitations, and offer some recommendations for future directions...
  14. ncbi CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences
    J A Johnson
    College of Pharmacy, University of Tennessee, Memphis, USA
    J Pharmacol Exp Ther 294:1099-105. 2000
    ..The observed racial differences in drug metabolism may have relevance to drug efficacy, toxicity, or carcinogen activation for CYP1A2 or CYP2D6 substrates...
  15. ncbi Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study
    Julie A Johnson
    University of Florida College of Pharmacy and Center for Pharmacogenomics, Gainesville, USA
    Am Heart J 157:442-9. 2009
    ..Selection of antihypertensive therapy is often empiric, and use of genetic information to guide drug therapy selection holds future promise...
  16. ncbi Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order
    J A Johnson
    College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 86:533-9. 2009
    ..In HCTZ/atenolol combination antihypertensive therapy, the order in which the drugs are initiated affects total BP lowering during the first 4-6 months of therapy...
  17. ncbi A summer research training program to foster PharmD students' interest in research
    Julie A Johnson
    Department of Pharmacy Practice, College of Pharmacy, Health Science Center, University of Florida, Gainesville, FL 32610 0486, USA
    Am J Pharm Educ 72:23. 2008
    ..To establish and assess the effectiveness of a 10-week summer research program on increasing doctor of pharmacy (PharmD) students' interest in research, particularly as it related to future career choices...
  18. ncbi Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol
    Julie A Johnson
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, 32610, USA
    Clin Pharmacol Ther 74:44-52. 2003
    ..We tested the hypothesis that 2 common polymorphisms in the gene for beta(1)-adrenergic receptor are associated with antihypertensive response to metoprolol in patients with uncomplicated hypertension...
  19. ncbi Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics
    Julie A Johnson
    Department of Pharmacy Practice, College of Pharmacy, Center for Pharmacogenomics, University of Florida, Gainesville, Florida 32610, USA
    Pharm Res 19:1779-87. 2002
    ..Further study of the betaAR genetic polymorphisms is likely to enhance our understanding of cardiovascular disease and improve our use of beta-agonists and beta-antagonists in treatment of cardiovascular disease...
  20. ncbi Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity
    Julie A Johnson
    University of Florida, Box 100486, Gainesville, FL 32610 0486, USA
    Trends Mol Med 8:300-5. 2002
    ....
  21. ncbi Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges
    Julie A Johnson
    University of Florida, Gainesville, Florida 32610 0486, USA
    Pharmacogenetics 13:525-34. 2003
    ..The knowledge necessary to move forward on all these fronts is not yet available, but will be increasingly accessible over the next few years...
  22. ncbi Pharmacogenetics: potential for individualized drug therapy through genetics
    Julie A Johnson
    Department of Pharmacy Practice, Department of Pharmaceutics and Department of Medicine, University of Florida, Box 100486, Gainesville, FL 32610-0486, USA
    Trends Genet 19:660-6. 2003
  23. ncbi Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics
    Julie A Johnson
    Department of Pharmacy Practice, Pharmaceutics and Medicine, Center for Pharmacogenomics, University of Florida, Gainesville, FL 32610-0486, USA
    Circulation 118:1383-93. 2008
  24. ncbi Pharmacogenetics of cardiovascular drugs
    Julie A Johnson
    Center for Pharmacogenomics, University of Florida, USA
    Brief Funct Genomic Proteomic 1:66-79. 2002
    ....
  25. ncbi G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension
    Alexander G Vandell
    Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida College of Pharmacy, 1600 SW Archer Rd, Room PG 22, Box 100486, Gainesville, FL 32610 0486, USA
    Hypertension 60:957-64. 2012
    ..The associations with GRK4 variant alleles were stronger in patients who were also ADRB1 389R homozygotes, suggesting a potential interaction between these 2 genes...
  26. ncbi Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure
    Maximilian T Lobmeyer
    Department of Pharmacy Practice, University of Florida, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 17:277-82. 2007
    ..We tested whether the ADRA2C insertion/deletion polymorphism was associated with beta-blocker response in heart failure, either alone or in combination with the ADRB1Arg389Gly polymorphism...
  27. ncbi Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
    Steven G Terra
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 15:227-34. 2005
    ..We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the beta1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to beta-blocker therapy among heart failure patients...
  28. ncbi CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
    Amber L Beitelshees
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA
    Circ Cardiovasc Genet 2:362-70. 2009
    ..The gene encoding the target of calcium channel blockers, the alpha1c-subunit of the L-type calcium channel (CACNA1C), has not been well characterized, and only small pharmacogenetic studies testing this gene have been published to date...
  29. ncbi KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)
    Amber L Beitelshees
    Department of Pharmacy Practice, University of Florida, College of Pharmacy, Gainesville, USA
    Pharmacogenet Genomics 17:719-29. 2007
    ....
  30. ncbi Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease
    Yan Gong
    Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Circ Cardiovasc Genet 4:169-78. 2011
    ..We investigated the hypothesis that 9p21 polymorphisms are associated with increased risk for adverse cardiovascular outcomes in patients with documented CAD...
  31. ncbi Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide
    Julio D Duarte
    Center for Pharmacogenomics and Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA
    J Transl Med 10:56. 2012
    ..This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure...
  32. ncbi Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)
    Tobias Gerhard
    College of Pharmacy, University of Florida, Gainesville, FL 32610 0486, USA
    Am Heart J 156:397-404. 2008
    ..The alpha-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists...
  33. ncbi Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation
    Michael A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA
    J Transl Med 6:11. 2008
    ..Adrenergic gene polymorphisms are associated with cardiovascular and metabolic phenotypes. We investigated the influence of adrenergic gene polymorphisms on cardiovascular risk in women with suspected myocardial ischemia...
  34. ncbi Systolic blood pressure and subjective well-being in patients with coronary artery disease
    Yan Gong
    College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Clin Cardiol 32:627-32. 2009
    ..Limited information exists regarding the association between subjective well-being (SWB) and systolic blood pressure (SBP) among hypertensive patients with coronary artery disease (CAD)...
  35. ncbi Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients
    Maximilian T Lobmeyer
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
    Pharmacogenet Genomics 21:42-9. 2011
    ....
  36. ncbi beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure
    Steven G Terra
    Department of Pharmacy Practice, University of Florida, Gainsville, FL 32610, USA
    Clin Pharmacol Ther 77:127-37. 2005
    ..We also tested whether polymorphisms in the beta(2)-adrenergic receptor, G-protein alpha s subunit (G(s)alpha), and cytochrome P450 (CYP) 2D6 genes or S-metoprolol plasma concentrations were associated with beta-blocker tolerability...
  37. ncbi Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study
    ELVIN TYRONE PRICE
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Medicine, Gainesville, FL, USA
    Pharmacogenet Genomics 21:333-40. 2011
    ....
  38. ncbi Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure
    Jaekyu Shin
    College of Pharmacy, Gainesville, Florida, USA
    Am J Cardiol 99:250-5. 2007
    ..In conclusion, ADRB2 Arg16Gln27 haplotype may significantly increase the risk of adverse outcomes in patients with HF receiving contemporary HF pharmacotherapy...
  39. ncbi Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)
    Yuxin Niu
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Circ Cardiovasc Genet 3:548-55. 2010
    ..Single-nucleotide polymorphisms (SNPs) within the regulatory β2 subunit of the voltage-gated calcium channel (CACNB2) may contribute to variable treatment response to antihypertensive drugs and adverse cardiovascular outcomes...
  40. ncbi Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
    Christina L Aquilante
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Clin Pharmacol Ther 79:291-302. 2006
    ....
  41. ncbi Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study)
    Martin Brunner
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, USA
    Am J Cardiol 99:1549-54. 2007
    ..Race was associated with diastolic BP response, although the difference is likely not to be clinically significant and AGTR1 genotype was not associated with BP response...
  42. ncbi Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1600 SW Archer Rd, Box 100486, Gainesville, FL 32610 0486, USA
    Hypertension 55:61-8. 2010
    ..19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity...
  43. ncbi Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit
    Yan Gong
    Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 17:267-75. 2007
    ....
  44. ncbi Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension
    Amber L Beitelshees
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida 32610-0486, USA
    Pharmacotherapy 26:1247-54. 2006
    ..24, p=0.105). CONCLUSION: Reliance on clinic blood pressure or resting heart rate for making beta-blocker treatment decisions may yield less than optimal assessment of the antihypertensive response or degree of beta-blockade...
  45. ncbi Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
    Steven M Smith
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Pharmacotherapy 29:1157-65. 2009
    ..To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients...
  46. ncbi Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension
    Michael A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida, USA
    Am J Hypertens 22:748-53. 2009
    ..We examined genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure (BP) control, and cardiovascular events in elderly, hypertensive coronary artery disease (CAD) patients...
  47. ncbi Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography
    Christina L Aquilante
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Am J Cardiol 94:535-8. 2004
    ..Gender and racial differences in blood pressure response merit consideration as potential contributors to the suboptimal response in dobutamine stress testing...
  48. ncbi Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure
    Christina L Aquilante
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, 32610, USA
    J Card Fail 12:171-6. 2006
    ..0005, respectively). CONCLUSION: These data suggest that with twice daily dosing, metoprolol IR is inferior to metoprolol XL in its effects on heart rate variability, autonomic balance, and blood pressure in patients with heart failure...
  49. ncbi Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension
    Issam Zineh
    Department of Pharmacy Practice, University of Florida, Gainesville, FL 32610, USA
    Clin Pharmacol Ther 76:536-44. 2004
    ..We investigated whether metoprolol plasma concentrations, CYP2D6 polymorphisms, or genotype-derived phenotype was associated with adverse effects or efficacy in patients with hypertension...
  50. ncbi Hypertension susceptibility Loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study
    Yan Gong
    Department of Pharmacotherapy and Translational Research
    Circ Cardiovasc Genet 5:686-91. 2012
    ..Clinical Trial Registration Information- clinicaltrials.gov; Identifier: NCT00246519...
  51. ncbi Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals
    Myphuong T Le
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA
    PLoS ONE 8:e52062. 2013
    ....
  52. ncbi Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects
    Myphuong T Le
    Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA
    Metabolism 61:641-51. 2012
    ..Compared with sucrose, HFCS leads to greater fructose systemic exposure and significantly different acute metabolic effects...
  53. ncbi Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin
    Jaekyu Shin
    College of Pharmacy and Center for Pharmacogenomics, University of Florida, Health Science Center, Gainesville, FL 32610 0486, USA
    Pharmacotherapy 31:942-50. 2011
    ..35, p=0.049). Conclusion. Our data suggest that the CYP3A5 genotype has minimal effects on the pharmacokinetic parameters of atorvastatin and its interaction with clarithromycin; these effects are unlikely to be clinically significant...
  54. ncbi Modeling sequence-sequence interactions for drug response
    Min Lin
    Department of Statistics, University of Florida, Gainesville, FL 32611, USA
    Bioinformatics 23:1251-7. 2007
    ..With the availability of large-scale, high-density single nucleotide polymorphism markers, a great challenge is how to associate haplotype structures and complex drug response through its underlying pharmacodynamic mechanisms...
  55. ncbi Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide
    Julio D Duarte
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida 32610, USA
    Pharmacogenet Genomics 20:516-9. 2010
    ..These data suggest that common variants in STK39 likely do not have a clinically relevant role in blood pressure response to HCTZ in hypertensives...
  56. ncbi Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia
    Landry K Kamdem
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pharmacogenet Genomics 18:507-14. 2008
    ..One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension...
  57. ncbi Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease
    Mustafa Hassan
    Cardiovascular Research, Division of Cardiology, Department of Medicine, College of Pharmacy, University of Florida, 1601 SW Archer Rd, Code 111 D, Gainesville, FL 32608, USA
    Arch Intern Med 168:763-70. 2008
    ....
  58. ncbi Pharmacogenetics of beta-blockers
    Jaekyu Shin
    College of Pharmacy, Center for Pharmacogenetics, University of Florida, Gainesville, Florida 32610 0486, USA
    Pharmacotherapy 27:874-87. 2007
    ..This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice...
  59. ncbi Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward
    Steven G Terra
    Department of Pharmacy Practice, University of Florida, Gainesville, Florida 32610, USA
    Am J Cardiovasc Drugs 2:287-96. 2002
    ..Finally, pharmacogenomics is likely to transform the way clinical trials are conducted by allowing for the selection of a more homogeneous study population, thereby reducing the size and cost of clinical investigation...
  60. ncbi Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics
    Caitrin W McDonough
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, Florida 32610 0486, USA
    J Hypertens 31:698-704. 2013
    ..We sought to further evaluate associations between NEDD4L polymorphisms, blood pressure response and cardiovascular outcomes with thiazide diuretics and β-blockers...
  61. ncbi Atenolol exposure and risk for development of adverse metabolic effects: a pilot study
    Hrishikesh A Navare
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, College of Medicine, University of Florida, Gainesville, Florida 32610 0486, USA
    Pharmacotherapy 30:872-8. 2010
    ..To evaluate whether the level of systemic exposure to atenolol explains observed interindividual differences in adverse metabolic responses...
  62. ncbi Pharmacogenetics of chronic cardiovascular drugs: applications and implications
    Issam Zineh
    University of Florida College of Pharmacy, Department of Pharmacy Practice and Center for Pharmacogenomics, 1600 SW Archer Rd, Room PG 06, PO Box 100486, Gainesville, FL 32610, USA
    Expert Opin Pharmacother 7:1417-27. 2006
    ....
  63. ncbi Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension
    Mohamed Shafiu
    College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Fla, USA mshafiu rapadocs com
    Kidney Blood Press Res 35:477-82. 2012
    ..URAT1 is a urate transporter, and we tested the association of URAT1 transporter gene (SLC22A12) polymorphisms with obesity and the metabolic syndrome in hypertensive subjects...
  64. ncbi Sequencing complex diseases With HapMap
    Tian Liu
    Department of Statistics, University of Florida, Gainesville 32611, USA
    Genetics 168:503-11. 2004
    ..The implications and extensions of our model are discussed...
  65. ncbi Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort
    Jason H Karnes
    Division of Clinical Pharmacology, Vanderbilt University, Nashiville, TN 37232 0575, USA
    J Transl Med 11:12. 2013
    ....
  66. ncbi Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory
    Christina L Aquilante
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville 32610, USA
    Pharmacotherapy 24:720-6. 2004
    ..To compare the accuracy, speed, and cost of two methodologies used for genotyping known variants in the cytochrome P450 (CYP) 2C9 metabolizing enzyme gene...
  67. ncbi Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (ALOX5) by pyrosequencing assay
    Anzeela M Schentrup
    Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
    Genet Test Mol Biomarkers 13:361-5. 2009
    ....
  68. ncbi Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure
    Jaekyu Shin
    College of Pharmacy, University of Florida, Gainesville, Florida, USA
    J Card Fail 13:656-62. 2007
    ..We tested whether an altered diurnal BP pattern is associated with adverse outcomes (death or hospitalization for HF exacerbation) in patients with HF...
  69. ncbi Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil
    T Y Langaee
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, Florida, USA
    Clin Pharmacol Ther 81:386-91. 2007
    ..CYP3A5 genotype does not contribute importantly to BP or risk of HTN, but may influence response to calcium channel blockers in populations in which carrier status of two functional alleles is common...
  70. ncbi Beta-blocker pharmacogenetics in heart failure
    Jaekyu Shin
    Department of Pharmacy Practice, College of Pharmacy, Center for Pharmacogenetics, University of Florida, P O Box 100486, Gainesville, FL 32610 0486, USA
    Heart Fail Rev 15:187-96. 2010
    ..This review summarizes the pharmacogenetic data for beta-blockers in patients with HF and discusses the potential implications of beta-blocker pharmacogenetics for HF patients...
  71. ncbi Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate
    Albert L Shroads
    Department of Medicine, Division of Endocrinology and Metabolism, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Clin Pharmacol 52:837-49. 2012
    ....
  72. ncbi Heart failure pharmacogenetics: past, present, and future
    Heather M Davis
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Curr Cardiol Rep 13:175-84. 2011
    ..This article reviews the literature in heart failure pharmacogenetics to date, opportunities for discovery in recent and upcoming clinical trials, as well as future directions in this field...
  73. ncbi Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry
    Jaekyu Shin
    College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 871:130-4. 2008
    ..The method is rapid, simple, precise and directly applicable to clarithromycin pharmacokinetic studies...
  74. ncbi PharmGKB submission update: IX. ADRB1 gene summary
    Michael A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida, Gainesmille, Florida, USA
    Pharmacol Rev 59:2-4. 2007
  75. ncbi beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension
    M A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida, USA
    Clin Pharmacol Ther 84:715-21. 2008
    ..ADRB1 haplotype variation is associated with mortality risk, and beta-blockers may be preferred in subgroups of patients defined by ADRB1 or ADRB2 polymorphisms...
  76. ncbi Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms
    Kiman Kim
    Department of Pharmaceutics, University of Florida, Gainesville, FL 32610, USA
    J Clin Pharmacol 44:1083-105. 2004
    ..Furthermore, these differences are relevant for international drug approval when regulatory agencies must decide if they accept results from clinical trials performed in other parts of the world...
  77. ncbi Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness
    Gary M Levin
    College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Mol Diagn Ther 11:155-60. 2007
    ..Roughly one-third of patients with depression do not respond to an initial trial of antidepressant medication treatment, possibly as a result of structural variations in the 5-HT(1A) receptor...
  78. ncbi Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies
    Tara Engeman Andrisin
    Department of Pharmacy Practice, Center for Pharmacogenomics, University of Florida, Gainesville 32610-0486, USA
    Pharmacotherapy 22:954-60. 2002
    ..Such an approach should be valuable to pharmacogenetic researchers and others who are conducting genetic research...
  79. ncbi Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study
    Larisa M Humma
    Department of Pharmacy Practice, University of Florida, Gainesville 32610-0486, USA
    Pharmacotherapy 22:939-46. 2002
    ..Withdrawal of beta-blockers the evening before DSE may be inadequate time for elimination of beta-blocker effect, requiring the addition of atropine to achieve the desired response during DSE...
  80. ncbi Metoprolol minimizes nighttime blood pressure dip in hypertensive black males
    J A Johnson
    Department of Clinical Pharmacy, College of Pharmacy, University of Memphis 38163, USA
    Am J Hypertens 8:254-9. 1995
    ..Since the nighttime decline in blood pressure is thought to protect against target organ damage, it may be important to identify antihypertensive agents which preserve or enhance the nighttime blood pressure dip...
  81. ncbi The evolving role of nesiritide in advanced or decompensated heart failure
    Issam Zineh
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, P O Box 100486, Gainesville, FL 32610, USA
    Pharmacotherapy 23:1266-80. 2003
    ..In addition, recommendations for its administration are provided, and unresolved therapeutic considerations are discussed...
  82. ncbi Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study
    S G Terra
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Int J Obes (Lond) 29:746-54. 2005
    ....
  83. ncbi Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics
    A L Beitelshees
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL 32610 0486, USA
    Pharmacogenomics J 6:174-8. 2006
    ..In addition, our data highlight the importance of measuring metoprolol concentration in order to account for variable pharmacokinetics and avoid misinterpretation of the data...
  84. ncbi Pharmacogenomics: the inherited basis for interindividual differences in drug response
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Annu Rev Genomics Hum Genet 2:9-39. 2001
    ..This chapter provides an overview of the current pharmacogenomics literature and offers insights for the potential impact of this field on the safe and effective use of medications...
  85. ncbi Genetic and clinical predictors of warfarin dose requirements in African Americans
    L H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 87:459-64. 2010
    ..No other VKORC1, CYP4F2, or APOE polymorphism contributed to the variance. The inclusion of additional CYP2C9 variants may improve the predictive ability of warfarin dosing algorithms for African Americans...
  86. ncbi A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis
    Xiang-Yang Lou
    Department of Statistics, University of Florida, Gainesville, Florida 32611, USA
    Genetics 163:1533-48. 2003
    ..The computer program for the method proposed in this article is available at the webpage http://www.ifasstat.ufl.edu/genome/~LD...
  87. ncbi Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography
    C L Aquilante
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Pharmacogenomics J 8:408-15. 2008
    ..These data suggest that the four selected beta(1)- and beta(2)-AR polymorphisms do not substantially influence the magnitude of hemodynamic response to dobutamine during DSE...
  88. ncbi Sequencing drug response with HapMap
    M Lin
    Department of Statistics, University of Florida, Gainesville, FL 32611, USA
    Pharmacogenomics J 5:149-56. 2005
    ..This model provides a powerful tool for elucidating the genetic variants of drug response and ultimately designing personalized medications based on each patient's genetic constitution...
  89. ncbi A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
    Gregory M Cooper
    Department of Genome Sciences, University of Washington, Seattle, WA98195, USA
    Blood 112:1022-7. 2008
    ..Randomized clinical trials that account for these 2 genes should therefore produce results that are definitive and broadly applicable...
  90. ncbi Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis
    Hao Jie Zhu
    Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
    Am J Hum Genet 82:1241-8. 2008
    ..Asp260fs, respectively, compared to the wild-type enzyme. These findings indicate that specific CES1 gene variants can lead to clinically significant alterations in pharmacokinetics and drug response of carboxylesterase 1 substrates...
  91. ncbi Creating and evaluating genetic tests predictive of drug response
    Scott T Weiss
    Channing Laboratory, Brigham and Women s Hospital, 181 Longwood Ave, Boston, Massachusetts 02115, USA
    Nat Rev Drug Discov 7:568-74. 2008
    ....
  92. ncbi CYP4F2 genetic variant alters required warfarin dose
    Michael D Caldwell
    Department of Surgery, Marshfield Clinic, Marshfield, WI, USA
    Blood 111:4106-12. 2008
    ..Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement...
  93. ncbi Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
    Danxin Wang
    Department of Pharmacology, Program in Pharmacogenetics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Blood 112:1013-21. 2008
    ..Increased warfarin dose requirement in blacks was accounted for by lower frequency of the -1639 A allele. Therefore, -1639G>A is a suitable biomarker for warfarin dosing across ethnic populations...
  94. ncbi Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147
    Tobias Gerhard
    Pharmacogenet Genomics 16:613. 2006
  95. ncbi Pharmacogenomics: challenges and opportunities
    Dan M Roden
    Vanderbilt University, Nashville, Tennessee, USA
    Ann Intern Med 145:749-57. 2006
    ..Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients...
  96. ncbi Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing
    Russ B Altman
    Stanford University, Department of Genetics and Bioengineering, Clark S172, Stanford, CA 94305-5444, USA
    Pharmacogenomics 8:519. 2007

Research Grants12

  1. Pharmacogenomic Evaluation of Antihypertensive Responses
    Julie Johnson; Fiscal Year: 2007
    ..The proposed efforts will be enhanced through conduct within the Pharmacogenetics Research Network, and availability of data and biological samples will be beneficial to other investigators in the field. ..
  2. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  3. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
    ..abstract_text> ..
  4. BETA-ADRENERGIC RECEPTOR POLYMORPHISMS AND HYPERTENSION
    Julie Johnson; Fiscal Year: 2003
    ..the BAR genotype significantly impacts the BP response to B-blockers could lead to improved patient outcomes, as patients could be genotyped prior to institution of B-blocker therapy, thus avoiding this therapy in those likely to respond ..
  5. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002
    ..Additionally, genotyping individuals early in age may help to identify those at increased risk of obesity prior to them becoming obese so that they may take appropriate preventive measures. ..